PharmaIN, Corp.

About

PharmaIN Corporation is a clinical-stage biopharmaceutical company based in Bothell, Washington. Founded in 2001, the company focuses on developing innovative subcutaneous, self-injectable peptide-based therapies for advanced liver cirrhosis, cancer, and related conditions. PharmaIN leverages its expertise in peptide engineering and drug delivery technologies to create effective and convenient treatment options that enhance patient quality of life. The company's pipeline includes several key candidates, such as PHIN-214, which is currently in a Phase 1 trial for liver cirrhosis, and PHIN-1314, which is in preclinical development for solid tumors. PharmaIN is actively seeking strategic partnerships to advance its clinical programs and has received funding for manufacturing and studies to support its drug development efforts. The leadership team comprises experienced professionals in drug development and biotechnology, dedicated to addressing unmet medical needs in chronic and complex diseases.